【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the World Market for Ovarian Cancer Treatment
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
1.10 Abbreviations Frequently Used in This Report
2. An Introduction to Ovarian Cancer Therapy
2.1 Overview of Ovarian Cancer
2.1.1 Symptoms of Ovarian Cancer
2.1.2 Risk Factors for Ovarian Cancer
2.1.3 Global Prevalence and Incidence of Ovarian Cancer
2.2 Diagnosing Ovarian Cancer
2.2.1 Laboratory Testing: The Uncertainty of CA 125 Testing
2.2.2 The Potential of Lysophosphatidic Acid Assay for Early Stage Ovarian Cancer
2.2.3 Imaging Studies for Diagnosing Ovarian Cancer
2.3 Treatment Options for Cancer
2.3.1 Chemotherapy
2.3.2 Targeted Therapy
2.3.3 Immunotherapy: Fastest Growing Sector in Cancer Therapy
2.3.3.1 Monoclonal Antibodies (mAbs)
2.3.3.2 Cancer Vaccines
2.3.3.3 Non-Specific Immunotherapies
2.3.4 Hormone Therapy
2.3.5 First-Line Therapy: Platinum-Taxane Treatment
2.3.6 Second-Line Therapy
2.3.7 Maintenance Therapy
3. Ovarian Cancer: World Market 2015-2025
3.1 Ovarian Cancer Therapies Market, 2014
3.1.1 A Note on Monoclonal Antibodies in this Report
3.2 Ovarian Cancer Therapies Market Forecast, 2015-2025
3.3 Driving and Restraining Forces Affecting the Ovarian Cancer Therapy Market
3.3.1 Increasing Patient Population
3.3.2 Intense Competition from Generics
3.4 The Ovarian Cancer Therapy Submarket Shares, 2019 and 2025
3.5 The Future of the World Market for Ovarian Cancer Therapy by Therapeutic Class: Grouped Revenue Forecasts, 2014-2025
3.5.1 Targeted Therapy—Leading Submarket in Ovarian Cancer Therapy by 2025
3.5.2 Chemotherapy—Remains First-Line Treatment for Ovarian Cancer
3.5.3 Immunotherapy—The Fastest Growing Segment in Cancer Therapy
3.5.4 Hormone Therapy—Rare Treatment in Ovarian Cancer
4. Leading Ovarian Cancer Drugs 2014
4.1 Avastin (Roche/Chugai) – The World Market Leader
4.1.1 Avastin Revenue, 2010-2014 – Mixed Growth
4.1.2 Avastin Ovarian Cancer Forecast, 2015-2025
4.2 Lynparza (AstraZeneca)
4.2.1 Lynparza Forecast 2015-2025
4.3 Yondelis (Zeltia/Johnson & Johnson)
4.3.1 Yondelis (Zeltia/Johnson & Johnson): Historical Revenues
4.3.2 Yondelis Forecast 2015-2025
4.4 Other Ovarian Cancer Therapies
5. Leading Regional and National Markets in the Ovarian Cancer Therapy 2015-2025
5.1 Regional Breakdown of the World Ovarian Cancer Therapeutics Market
5.1.1 How Will Regional Market Shares Change to 2025?
5.2 The US Ovarian Cancer Drug Therapy Market, 2014
5.2.1 US Ovarian Cancer Therapeutics Market Forecast, 2015-2025
5.3 The Ovarian Cancer Therapy Market in the EU5 Markets to 2025
5.3.1 German Ovarian Cancer Therapy Market Forecast, 2015-2025
5.3.2 French Ovarian Cancer Therapy Market Forecast, 2015-2025
5.3.3 UK: Pharmaceutical Price Regulation Scheme and Market Forecast, 2015-2025
5.3.3.1 NICE: Guidance for Ovarian Cancer Therapies
5.3.4 Spanish Ovarian Cancer Therapy Market Forecast, 2015-2025
5.3.5 Italian Ovarian Cancer Therapy Market Forecast, 2015-2025
5.4 Japan: Growth in Generics – Ovarian Cancer Therapy Market Forecast, 2015-2025
5.5 Chinese Ovarian Cancer Therapy Market Forecast, 2015-2025
5.6 Indian Ovarian Cancer Therapy Market Forecast, 2015-2025
5.7 Brazilian Ovarian Cancer Therapy Market Forecast, 2015-2025
5.8 Russian Ovarian Cancer Therapy Market Forecast, 2015-2025
6. Leading Companies in the Ovarian Cancer Therapy Market
6.1 Companies with Exclusivity in 2014
6.2 Johnson & Johnson (J&J)
6.2.1 Sales and Performance Analysis, 2014
6.2.2 Pharmaceutical Segment Sales Analysis, 2014
6.2.2.1 R&D Performance Analysis, 2014
6.2.3 Recent M&A Activity: J&J Acquires Alios BioPharma and Aragon Pharmaceuticals
6.3 Roche
6.3.1 Sales and Performance Analysis, 2014
6.3.2 Pharmaceutical Segment Sales Analysis, 2014
6.3.2.1 Cancer Drug Sales and Performance Analysis, 2014
6.3.2.2 Pharmaceutical Segment R&D Performance Analysis, 2014
6.3.3 Recent M&A Activity
6.4 AstraZeneca
6.4.1 Sales and Performance Analysis, 2014
6.4.2 Pharmaceutical Segment Sales Analysis, 2014
6.4.2.1 Cancer Drug Sales and Performance Analysis, 2014
6.4.2.2 R&D Performance Analysis, 2014
6.4.3 Recent M&A Activity: The Pfizer and AstraZeneca Saga
7. Ovarian Cancer Therapy: Developmental Pipelines 2015
7.1 Ovarian Cancer Phase III Candidates 2015
7.1.1 Niraparib (TESARO): Leading the PARP Inhibitors in the Pipeline
7.1.1.1 TESARO and Merck to Collaborate: Niraparib and Keytruda
7.1.2 Trebananib (Amgen/Takeda Pharmaceuticals): Misses Key Survival Measure in Phase III
7.1.3 Nintedanib (Boehringer Ingelheim): Triple Angiokinase Inhibitor
7.1.4 Recentin (AstraZeneca): Promising Results in Phase III
7.1.5 Rucaparib (Clovis Oncology): ARIEL2 and ARIEL3
7.1.6 Opaxio (CTI BioPharma): Biologically Enhanced Chemotherapeutic
7.1.7 Binimetinib (Array Biopharma): Expected Filing in 2016
7.1.8 Lurbinectedin (PharmaMar): Second-Generation Analogue of Yondelis (Trabectedin)
7.1.9 Virgil (Gradalis): Autologous Tumour Cell Vaccine
7.1.10 Farletuzumab (Eisai): Failure in Phase III
7.2 Ovarian Cancer Phase II Candidates 2015
7.2.1 CVac (Prima BioMed): MUC-1 Cancer Vaccine
7.2.2 SG2000 (Spirogen): Cytotoxic Technology Based on Pyrrolobenzodiazepines
7.2.3 Zoptarelin Doxorubicin (Aeterna Zentaris): Luteinising Hormone-Releasing Hormone (LHRH)
7.2.4 Reolysin (Oncolytics Biotech)
7.2.5 SGI110 (Astex Pharmaceuticals)
7.2.6 OvaRex (Quest PharmaTech)
7.2.7 Polyvalent Antigen-KLH Conjugate Vaccine (MabVax Therapeutics)
7.2.8 Motolimod (VentiRx Pharmaceuticals): Toll-Like Receptor 8 Agonist
7.2.9 Cyramza (Eli Lilly): Expanding Approved Indications
7.2.10 EGEN-001 (Celsion Corporation): IL-12 Immunotherapy
7.2.11 Ganetespib and Elesclomol (Synta Pharmaceuticals)
7.2.12 ENMD-2076 (CASI Pharmaceuticals)
7.2.13 GALE-301 (Galena Biopharma): Folate Binding Protein Vaccine
7.2.14 Epacadostat (Incyte Corporation): IDO1 Inhibitor
7.2.15 AZD1775 (AstraZeneca): WEE1 Kinase Inhibitor
7.2.16 Etirinotecan Pegol (Nektar Therapeutics): Promising Phase II Results
7.2.17 Linsitinib (Astellas Pharmaceuticals): Development Discontinued?
7.2.18 Afuresertib (GlaxoSmithKline): Multiple Oncology Indications
7.2.19 Zybrestat (OXiGENE): Vascular Disrupting Agent
7.2.20 Yervoy (Bristol-Myers Squibb)
7.2.21 Alisertib (Takeda Pharmaceuticals): Aurora A Kinase Inhibitor
7.2.22 Voxtalisib with Pimasertib (Sanofi and Merck Serono)
7.2.23 Eli Lilly’s Phase II Ovarian Cancer Pipeline: LY2606368, Olaratumab & Ralimetinib
7.2.24 MK2206 (Merck & Co.): AKT Inhibitor
7.2.25 A6 Peptide (Angstrom Pharma)
7.2.26 Lifastuzumab Vedotin (Roche): Antibody Drug Conjugate
7.3 Ovarian Cancer Phase II Candidates 2015
7.3.1 VBL-111 (VBL Therapeutics): Anti-Angiogenic Agent
7.3.2 MEDI4736 (AstraZeneca)
7.3.3 OVax (AVAX Technologies)
7.3.4 ME-344 (Novogen)
7.3.5 DPX-Survivac and DPX-0907 (Immunovaccine): Two Novel Immunotherapies
8. Qualitative Analysis of the Ovarian Cancer Therapy Market 2015-2025
8.1 SWOT Analysis of the Ovarian Cancer Therapeutics Market
8.1.1 Strengths and Weaknesses of the Market
8.1.2 The Rising Incidence of Cancer
8.1.3 Drug Development Challenges
8.2 Opportunities and Threats for the Market
8.2.1 Advances in Research Open the Doors for Personalised Therapy
8.3 Regulations and Pricing Restrictions
8.4 STEP Analysis of the Ovarian Cancer Therapy Market
8.4.1 Social Factors: An Expanding Patient Population and Increasing Awareness
8.4.2 Technological Advances: DNA Sequencing of High-Grade Serous Ovarian Carcinoma
8.4.3 Economic Factors: Cost Cutting in the EU and the US
8.4.4 Political Factors: Will the Affordable Care Act Increase Patient Access to Anti-Cancer Drugs?
8.5 Porter’s Five Forces Analysis of the Ovarian Cancer Therapeutics Market
8.5.1 Rivalry Among Competitors
8.5.2 Threat of New Entrants
8.5.3 Power of Suppliers
8.5.4 Power of Buyers
8.5.5 Threat of Substitutes
9. Research Interviews
9.1 Interview with Prof. Dror Harats, CEO, VBL Therapeutics
9.1.1 Outlook for VB-111 in the Ovarian Cancer Market
9.1.2 Drivers and Restraints in the Ovarian Cancer Market
9.1.3 Trends in the Ovarian Cancer Market
9.1.4 Outlook for VBL Therapeutics in the Oncology Market
9.2 Interview with Mr Stuart Roberts, Global Head of Investor Relations, Prima BioMed
9.2.1 Outlook for CVac in the Ovarian Cancer Market
9.2.2 The Ovarian Cancer Market
9.2.3 Trends in the Ovarian Cancer Market
9.2.4 Outlook for Prima BioMed in the Oncology Market
9.3 Interview with a Representative of OXiGENE
9.3.1 Outlook for Zybrestat in the Ovarian Cancer Market
9.3.2 The Ovarian Cancer Market in 2015
9.3.3 Trends in the Ovarian Cancer Market, 2015-2025
9.3.4 Outlook for OXiGENE in the Oncology Market
10. Conclusions from the Research and Analysis
10.1 The World Ovarian Cancer Therapeutics Market in 2014
10.1.1 Leading National Markets to 2025
10.2 Trends in the Industry
10.2.1 Growing Interest in Personalised Therapy
10.2.2 Multiple Late-Stage Pipeline Drugs
10.3 Concluding Remarks
【レポート販売概要】
■ タイトル：卵巣がん治療薬の世界市場：企業動向、研究開発、収益予測■ 英文：Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025
: Recently Approved Treatments Give High Market Potential
■ 発行日：2015年7月
■ 調査会社：visiongain
■ 商品コード：VGAIN5081914
■ 調査対象地域：グローバル
- 禁煙治療薬の世界市場：ニコチン置換療法（NRT）、電子たばこAbout Smoking Cessation Products Smoking cessation products such as NRTs and e-cigarettes have proved useful in reducing the numbers of smokers worldwide. They can also be used to reduce smoking. A substantial number of smokers are now either quitting or trying to reduce smoking. This is because of increased awareness about the adverse effects of smoking; it is associated with a number of health h …
- 冷蔵倉庫建設の世界市場予測（～2021）The global cold storage construction market is projected to reach USD 10.47 Billion by 2021, at a CAGR of 14.0% between 2016 and 2021. This growth is mainly attributed to the growth in the international trade of perishable and processed foods, growing consumer demand for temperature controlled items, and government support for development of cold stores. Among all storage types, the production sto …
- LBS（位置情報サービス）の世界市場：追跡、ナビゲーション、インフォテイメント、分析、レクリエーションおよびフィットネスAbout location-based services LBS use location-enabled devices to track the location of users within the range of a wireless network. This is done with the help of GIS and the Internet. Location-enabled mobile devices such as smartphones, tablets, PNDs; and location-enabled in-dash devices can search for places and routes; obtain traffic updates and real-time directions; provide information on cur …
- ドアホンの世界市場2016-2020：音声ドアホン、ビデオドアホンAbout Door Phone Door phones are a necessity in a modern household. They are simple in structure and are relatively inexpensive. Door phones can be used for both voice communication as well as video communication and are used in apartments, single-family residences or residential buildings, and others. Door phones can also be used in factories as well as different communities to identify the visit …
- 世界主要国の髄膜炎検査（医療機器）市場The report presents a detailed analysis of the Meningitis diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Meningitis definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - C …
- Petsec Energy Limited：石油・ガスの開発・生産動向及びコスト分析- Q1, 2013Petsec Energy Limited Oil & Gas Exploration and Production Operations and Cost Analysis - Q1, 2013 Summary Petsec Energy Limited Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source …
- 自動車バッテリー管理システムの世界市場2016-2020About Automotive Battery Management System A battery management system (BMS) is an electronic system that helps to monitor and manage the lifecycle of rechargeable batteries. This system helps to maintain optimum battery health by monitoring every charging cycle, controlling the load fluctuations, and balancing the charging levels. Technavio’s analysts forecast the global automotive battery manage …
- ビジュアル・コンピューティングの世界市場The visual computing market is expected to grow at a rapid pace in most of the regions of the world due to a growing number of acquisitions and the focus of the industry players for incorporating the technology in various application areas such as gaming, media & entertainment, healthcare, automotive, and so on. A high demand from the gaming sector coupled with rich graphics is a major factor whic …
- Location-based Services: Solutions and Market OpportunitiesThis report bundle is by far the most comprehensive research covering the market for Location-based Services (LBS) solutions and market opportunities. It covers cellular mobile location determination and related services as well as other location methods such as RFID. It includes research that covers market opportunities, company analysis, solution analysis, emerging opportunities, market vertical …
- ASICの世界市場2017-2021ABSTRACTAbout Application Specific IC ASIC is a microchip, designed for a specific application or purpose. ASICs are manufactured with custom designs as per the device configuration or end-user specification. The different microprocessors and memory cores are being included in an ASIC, which enables the limited software programmability with the software algorithm performed on the device. An ASIC i …
- 経腸栄養バックの世界市場2016-2020About Enteral Nutrition Enteral nutrition is preferred over parenteral nutrition because it is cost-effective and is considered for malnourished patients who have a functional GI tract but have difficulty in swallowing food. Medical conditions that require enteral feeding include malnutrition, neurologic disorders, swallowing disorders, anatomical or post-surgical malformations of the mouth, eosin …
- コールドチェーンの中国市場2017-2021ABSTRACTAbout Cold Chain A cold chain is an uninterrupted supply chain that includes a network of facilities and distribution options. Various stages and processes in this supply chain operate under controlled temperature and humidity. China’s cold chain system is growing exponentially, resulting in various enterprises integrating such systems for the preservation of their products. The government …
- 硬質プラスチックパッケージの世界市場：プラスチック製びん、プラスチック製バルク容器、プラスチック製ブリスターAbout Rigid Plastic Packaging Rigid plastic is a grade of plastic that is highly toughened and used for packaging of bulk and unit material. It is non-corrosive, light, cheap, and easily moldable, which makes it a perfect choice for packaging. Extrusion molding, injection molding, and blow molding are used to produce different rigid plastic packaging products. TechNavio's analysts forecast the Glo …
- ペプチドホルモンの世界市場及びパイプライン分析Human body consists of myriad of chemicals required for signaling, providing nutrients, proper growth and development. Hormones are one such chemical present in the body that plays a very important role in maintaining homeostasis. They are secreted from endocrine glands which are also known as duct less gland because hormones are directly secreted into the blood stream. Moreover, diversity could b …
- エネルギー管理システムの世界市場：ホームエネルギー管理システム（HEMS）、ビルエネルギー管理システム（BEMS）EMS is a systematic collaboration of tools and practices to track, analyze, and plan energy consumption in industrial and commercial (C&I), and residential sector. A high-tech and scalable EMS forms a building block to a sustainable future and also helps businesses monitor energy consumption and maintain usage efficiency to achieve best practices in managing energy resources which are expensive an …
